Pharsight

Dymista patents expiration

DYMISTA's oppositions filed in EPO
DYMISTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(11 months ago)

US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(11 months ago)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(8 months ago)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(5 months ago)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(2 months ago)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(1 year, 9 months from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(2 years from now)

Dymista is owned by Mylan Speciality Lp.

Dymista contains Azelastine Hydrochloride; Fluticasone Propionate.

Dymista has a total of 7 drug patents out of which 5 drug patents have expired.

Expired drug patents of Dymista are:

  • US9259428
  • US9901585
  • US8163723
  • US9259428*PED
  • US8163723*PED

Dymista was authorised for market use on 01 May, 2012.

Dymista is available in spray, metered;nasal dosage forms.

Dymista can be used as treatment of seasonal allergic rhinitis.

The generics of Dymista are possible to be released after 24 August, 2026.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Feb 20, 2018
Pediatric Exclusivity(PED) Aug 20, 2018
New Combination(NC) May 01, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents